Long-Term Clinical and Safety Outcomes of Canaloplasty Performed across All Grades of Glaucoma Severity

Table 2

Mean reduction in IOP and number of medications for (1) all patients; (2) combined group vs. standalone group; (3) mild-moderate group vs. severe glaucoma group; and (4) controlled group vs. uncontrolled group.

	Baseline (n = 72)		Post-op (n = 72)		value
IOP
Mean (SD)	18.6 (5.8)		13.5 (4.7)		<0.001
Mean reduction	—		24.5%
Meds
Mean (SD)	2.36 (1.0)		1.63 (1.2)		<0.001
Mean reduction	—		29.2%
	Combined			Standalone
	Baseline (n = 63)	Post-op (n = 63)	value	Baseline (n = 9)	Post-op (n = 9)	value
IOP
Mean (SD)	18.52 (5.6)	13.68 (4.8)	<0.001	19.33 (7.7)	12.44 (4.4)	=0.021
Mean reduction	—	26.1%		—	35.6%
Meds
Mean (SD)	2.32 (1.0)	1.57 (1.2)	<0.001	2.67 (0.7)	2.00 (1.4)	=0.262
Mean reduction	—	32.2%		—	25.0%
Eyes combined with phacoemulsification (N = 63)
	Mild-moderate			Severe
	Baseline (n = 43)	Post-op (n = 43)	value	Baseline (n = 20)	Post-op (n = 20)	value
IOP
Mean (SD)	18.77 (5.7)	13.56 (3.7)	<0.001	18.00 (5.4)	13.95 (6.6)	=0.004
Mean reduction	—	27.8%		—	22.5%
Meds
Mean (SD)	2.23 (1.0)	1.35 (1.3)	<0.001	2.50 (0.9)	2.05 (0.8)	=0.046
Mean reduction	—	39.6%		—	−18.0%
	Controlled			Uncontrolled
	Baseline (n = 39)	Post-op (n = 39)	value	Baseline (n = 24)	Post-op (n = 24)	value
IOP
Mean (SD)	15.15 (2.2)	12.05 (2.6)	<0.001	24.00 (5.1)	16.33 (6.2)	<0.001
Mean reduction	—	20.5%		—	31.9%
Meds
Mean (SD)	2.31 (1.0)	1.49 (1.1)	<0.001	2.33 (1.0)	1.71 (1.2)	=0.001
Mean reduction	—	35.6%		—	26.8%